USD0.000æéå€ååŒÂ  (ET)
4.40BæäŸ¡ç·é¡
40.53çŽè¿12ã¶æPER
äž»èŠããŒã¿
80.560å§å€
81.780é«å€
514.70Kåºæ¥é«
40.53çŽè¿12ã¶æPER
16.87äºæ³PER
--çŽè¿12ã¶æé
åœ
0.94%売買å転ç
81.050忥çµå€
79.294å®å€
30.95M売買代é
69.58æ ªäŸ¡åçç
3.63PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
4.22%ç·è³ç£å©çç
75.81552é±é«å€
0.96åºæ¥é«æ¯ç%
63.23MçŽå©ç
54.90Mæ ªåŒæ°
1.97721æ ªåœããå©çïŒEPSïŒ
0.87ããŒã¿å€
9.54%èªå·±è³æ¬å©çç
41.01552é±å®å€
3.07%æ¯ãå¹
67.29%ç²å©çç
4.40BæäŸ¡ç·é¡
-1.85ãªã¹ã¯ãªã¿ãŒã³
1.92%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-31 äž»èŠã€ã³ãµã€ã
LivaNova PLCã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçéåžžã«å¥å
šã§ããæé·ã®å¯èœæ§ã¯é«ãã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸããå»çæ©åš & å忥çã§ã®é äœã¯199äž22äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ããè²·ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯84.93ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯äžæãã¬ã³ããšäºæ³ãããŸããéå»1ãæã®æ ªåŒåžå Žã®ããã©ãŒãã³ã¹ã¯å¹³åçã§ããããå瀟ã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯å
調ã§ããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
LivaNova PLCã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
LivaNova PLCã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
LivaNova PLC ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
Zimmer Biomet Holdings Inc
ZBH
31
ææšî
ææš
売ã(2)
äžç«(4)
è²·ã(1)
ç§»åå¹³å
売ã(2)
äžç«(0)
è²·ã(4)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
LivaNova PLCã®äŒæ¥æ
å ±î
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
äŒæ¥ã³ãŒãLIVN
äŒæ¥åLivaNova PLC
æé«çµå¶è²¬ä»»è
ãCEOãMakatsaria (Vladimir A)
ãŠã§ããµã€ãhttps://www.livanova.com/
æ ªäž»çµ±èšî
ãããã質å
LivaNova PLCïŒLIVNïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îLivaNova PLCïŒLIVNïŒã®çŸåšã®æ ªäŸ¡ã¯80.14ã§ãã
LivaNova PLCã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îLivaNova PLCã®ãã£ãã«ãŒã·ã³ãã«ã¯LIVNã§ãã
LivaNova PLCã®52é±é«å€ã¯ãããã§ããïŒ
îLivaNova PLCã®52é±é«å€ã¯75.81ã§ãã
LivaNova PLCã®52é±å®å€ã¯ãããã§ããïŒ
îLivaNova PLCã®52é±å®å€ã¯41.02ã§ãã
LivaNova PLCã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îLivaNova PLCã®æäŸ¡ç·é¡ã¯4.40Bã§ãã
LivaNova PLC (LIVN) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãLivaNova PLCïŒLIVNïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯84.93ã§ãã
LivaNova PLC (LIVN) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îLivaNova PLCïŒLIVNïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-4.45ã§ãã